Dell falls as soft current quarter guide offsets Q2 beat, full-year outlook lift
Kim Mina, the Chief Executive Officer of Acelyrin, Inc. (NASDAQ:SLRN), a $284 million market cap biotech company, recently sold 17,986 shares of the company’s common stock. The shares were sold at a weighted average price of $2.744, totaling $49,353. Following this transaction, Mina holds 671,753 shares directly. According to InvestingPro analysis, SLRN’s stock has declined 47% over the past six months, though current metrics suggest the stock is trading below Fair Value.
The sale was conducted as part of Acelyrin’s policy to cover tax obligations related to the vesting and settlement of restricted stock units, and was not a discretionary sale by the CEO. The shares were sold in multiple transactions, with prices ranging between $2.71 and $2.76. InvestingPro data shows the company maintains strong liquidity with a current ratio of 7.15 and holds more cash than debt on its balance sheet. Discover 8 more key insights about SLRN with an InvestingPro subscription, including detailed financial health metrics and growth projections.
In other recent news, Acelyrin Inc. has been at the center of several significant developments. The company recently confirmed an unsolicited buyout proposal from Concentra Biosciences, offering $3.00 per share plus a contingent value right, as it navigates a pending merger with Alumis Inc., expected to finalize in the second quarter of 2025. In another strategic move, Acelyrin terminated its License and Collaboration Agreement with Affibody AB, ending its rights to develop the therapeutic product izokibep. Additionally, Acelyrin has adopted a stockholder rights plan in response to Tang Capital Partners (WA:CPAP) acquiring 8.8% of its shares, with the plan set to expire in March 2026.
On the analyst front, Citi adjusted Acelyrin’s stock target to $3.00 from $6.00, maintaining a Neutral rating due to uncertainties in the Phase 3 program for lonigutamab, a treatment for thyroid eye disease. H.C. Wainwright also revised the stock target to $6.00 from $8.00, citing recent data from the Phase 1/2 study of lonigutamab and the upcoming Phase 3 program. The Phase 3 program is set to begin in the first quarter of 2025 with a new dosing regimen. These developments reflect the dynamic environment surrounding Acelyrin as it continues to focus on its strategic goals and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.